664 related articles for article (PubMed ID: 25830489)
1. Immunogenicity and safety of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) co-administered with DTPa vaccine in Japanese children: A randomized, controlled study.
Iwata S; Kawamura N; Kuroki H; Tokoeda Y; Miyazu M; Iwai A; Oishi T; Sato T; Suyama A; François N; Shafi F; Ruiz-Guiñazú J; Borys D
Hum Vaccin Immunother; 2015; 11(4):826-37. PubMed ID: 25830489
[TBL] [Abstract][Full Text] [Related]
2. Safety, reactogenicity and immunogenicity of 2-dose catch-up vaccination with 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Malian children in the second year of life: Results from an open study.
Dicko A; Dicko Y; Barry A; Sidibe Y; Mahamar A; Santara G; Dolo A; Diallo A; Doumbo O; Shafi F; François N; Yarzabal JP; Strezova A; Borys D; Schuerman L
Hum Vaccin Immunother; 2015; 11(9):2207-14. PubMed ID: 26020101
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) when coadministered with different neisseria meningitidis serogroup C conjugate vaccines.
Wysocki J; Tejedor JC; Grunert D; Konior R; Garcia-Sicilia J; Knuf M; Bernard L; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2009 Apr; 28(4 Suppl):S77-88. PubMed ID: 19325450
[TBL] [Abstract][Full Text] [Related]
4. Immunogenicity and safety of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) co-administered with routine childhood vaccines in Taiwan.
Lin TY; Lu CY; Chang LY; Chiu CH; Huang YC; Bock HL; Tang H; François N; Moreira M; Schuerman L; Huang LM
J Formos Med Assoc; 2012 Sep; 111(9):495-503. PubMed ID: 23021506
[TBL] [Abstract][Full Text] [Related]
5. Immunogenicity and safety of 11- and 12-valent pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccines (11vPHiD-CV, 12vPHiD-CV) in infants: Results from a phase II, randomised, multicentre study.
Carmona Martinez A; Prymula R; Miranda Valdivieso M; Otero Reigada MDC; Merino Arribas JM; Brzostek J; Szenborn L; Ruzkova R; Horn MR; Jackowska T; Centeno-Malfaz F; Traskine M; Dobbelaere K; Borys D
Vaccine; 2019 Jan; 37(1):176-186. PubMed ID: 30054160
[TBL] [Abstract][Full Text] [Related]
6. Safety and immunogenicity of 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Nigerian children: Booster dose and 2-dose catch-up regimens in the second year of life.
Odusanya OO; Kuyinu YA; Kehinde OA; Shafi F; François N; Yarzabal JP; Dobbelaere K; Rüggeberg JU; Borys D; Schuerman L
Hum Vaccin Immunother; 2014; 10(3):757-66. PubMed ID: 24356787
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity, Safety and Reactogenicity of a Booster Dose of the 10-Valent Pneumococcal Nontypeable H. influenzae Protein D Conjugate Vaccine Coadministered With DTPa-IPV-Hib in Dutch Children: A Randomized Controlled Trial.
van den Bergh MR; Spijkerman J; François N; Swinnen K; Borys D; Schuerman L; Veenhoven RH; Sanders EA
Pediatr Infect Dis J; 2016 Jul; 35(7):e206-19. PubMed ID: 27097348
[TBL] [Abstract][Full Text] [Related]
8. Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal non-typeable Hemophilus influenzae protein D conjugate vaccine (PHiD-CV) when co-administered with the DTPw-HBV/Hib vaccine in Indian infants: a single-blind, randomized, controlled study.
Lalwani S; Chatterjee S; Chhatwal J; Verghese VP; Mehta S; Shafi F; Borys D; Moreira M; Schuerman L
Hum Vaccin Immunother; 2012 May; 8(5):612-22. PubMed ID: 22634448
[TBL] [Abstract][Full Text] [Related]
9. Immunologic non-inferiority and safety of the investigational pneumococcal non-typeable Haemophilus influenzae protein D-conjugate vaccine (PHiD-CV) 4-dose vial presentation compared to the licensed PHiD-CV 1-dose vial presentation in infants: A phase III randomized study.
Zaman K; Zaman SF; Zaman F; Aziz A; Faisal SB; Traskine M; Habib MA; Ruiz-Guiñazú J; Borys D
Vaccine; 2018 Jan; 36(5):698-706. PubMed ID: 29277353
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and Safety of 10-valent Pneumococcal Nontypeable Haemophilus influenzae Protein D Conjugate Vaccine (PHiD-CV) Administered to Children With Sickle Cell Disease Between 8 Weeks and 2 Years of Age: A Phase III, Open, Controlled Study.
Sirima SB; Tiono A; Gansané Z; Siribié M; Zongo A; Ouédraogo A; François N; Strezova A; Dobbelaere K; Borys D
Pediatr Infect Dis J; 2017 May; 36(5):e136-e150. PubMed ID: 28403055
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity, safety, and reactogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine and DTPa-IPV-Hib when coadministered as a 3-dose primary vaccination schedule in The Netherlands: a randomized controlled trial.
van den Bergh MR; Spijkerman J; François N; Swinnen K; Borys D; Schuerman L; Veenhoven RH; Sanders EA
Pediatr Infect Dis J; 2011 Sep; 30(9):e170-8. PubMed ID: 21487327
[TBL] [Abstract][Full Text] [Related]
12. Safety and immunogenicity of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Chilean children.
Lagos RE; Muñoz AE; Levine MM; Lepetic A; François N; Yarzabal JP; Schuerman L
Hum Vaccin; 2011 May; 7(5):511-22. PubMed ID: 21441782
[TBL] [Abstract][Full Text] [Related]
13. Immunogenicity, safety and reactogenicity of the pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in 2-17-year-old children with asplenia or splenic dysfunction: A phase 3 study.
Szenborn L; Osipova IV; Czajka H; Kharit SM; Jackowska T; François N; Habib MA; Borys D
Vaccine; 2017 Sep; 35(40):5331-5338. PubMed ID: 28866290
[TBL] [Abstract][Full Text] [Related]
14. Immunogenicity and safety of a booster dose of the 13-valent pneumococcal conjugate vaccine in children primed with the 10-valent or 13-valent pneumococcal conjugate vaccine in the Czech Republic and Slovakia.
Urbancikova I; Prymula R; Goldblatt D; Roalfe L; Prymulova K; Kosina P
Vaccine; 2017 Sep; 35(38):5186-5193. PubMed ID: 28797727
[TBL] [Abstract][Full Text] [Related]
15. Induction of immunologic memory following primary vaccination with the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in infants.
Knuf M; Pankow-Culot H; Grunert D; Rapp M; Panzer F; Köllges R; Fanic A; Habib A; Borys D; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2012 Jan; 31(1):e31-6. PubMed ID: 21909049
[TBL] [Abstract][Full Text] [Related]
16. Safety and immunogenicity of a booster dose of the 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine coadministered with measles-mumps-rubella-varicella vaccine in children aged 12 to 16 months.
Vesikari T; Karvonen A; Lindblad N; Korhonen T; Lommel P; Willems P; Dieussaert I; Schuerman L
Pediatr Infect Dis J; 2010 Jun; 29(6):e47-56. PubMed ID: 20508478
[TBL] [Abstract][Full Text] [Related]
17. Response to primary and booster vaccination with 10-valent pneumococcal nontypeable Haemophilus influenzae protein D conjugate vaccine in Korean infants.
Kim CH; Kim JS; Cha SH; Kim KN; Kim JD; Lee KY; Kim HM; Kim JH; Hyuk S; Hong JY; Park SE; Kim YK; Kim NH; Fanic A; Borys D; Ruiz-Guiñazù J; Moreira M; Schuerman L; Kim KH
Pediatr Infect Dis J; 2011 Dec; 30(12):e235-43. PubMed ID: 21817957
[TBL] [Abstract][Full Text] [Related]
18. Immunogenicity, safety and reactogenicity of the 10-valent pneumococcal non-typeable haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in Nigerian Infants: a randomised trial.
Odusanya OO; Kuyinu YA; Kehinde OA; Francois N; Yarzabal JP; Moreira M; Borys D; Schuerman L
Niger Postgrad Med J; 2013 Dec; 20(4):272-81. PubMed ID: 24633268
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and safety of a novel ten-valent pneumococcal conjugate vaccine in healthy infants in The Gambia: a phase 3, randomised, double-blind, non-inferiority trial.
Clarke E; Bashorun A; Adigweme I; Badjie Hydara M; Umesi A; Futa A; Ochoge M; Obayemi D; Edem B; Saidy-Jah E; Onwuchekwa C; Dhere R; Sethna V; Kampmann B; Goldblatt D; Taylor D; Andi-Lolo I; Hosken N; Antony K; Innis BL; Alderson MR; Lamola S
Lancet Infect Dis; 2021 Jun; 21(6):834-846. PubMed ID: 33516293
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of pneumococcal nontypable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in young Latin American children: A double-blind randomized controlled trial.
Tregnaghi MW; Sáez-Llorens X; López P; Abate H; Smith E; Pósleman A; Calvo A; Wong D; Cortes-Barbosa C; Ceballos A; Tregnaghi M; Sierra A; Rodriguez M; Troitiño M; Carabajal C; Falaschi A; Leandro A; Castrejón MM; Lepetic A; Lommel P; Hausdorff WP; Borys D; Ruiz Guiñazú J; Ortega-Barría E; Yarzábal JP; Schuerman L;
PLoS Med; 2014 Jun; 11(6):e1001657. PubMed ID: 24892763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
